Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.570
-0.130 (-2.77%)
At close: Nov 14, 2025, 4:00 PM EST
4.523
-0.048 (-1.04%)
After-hours: Nov 14, 2025, 5:51 PM EST
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $1.80M in the quarter ending June 30, 2025, with 41.49% growth. This brings the company's revenue in the last twelve months to $4.17M, down -62.68% year-over-year. In the year 2024, Bolt Biotherapeutics had annual revenue of $7.69M, down -2.36%.
Revenue (ttm)
$4.17M
Revenue Growth
-62.68%
P/S Ratio
2.10
Revenue / Employee
$80,135
Employees
52
Market Cap
8.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.69M | -186.00K | -2.36% |
| Dec 31, 2023 | 7.88M | 2.15M | 37.48% |
| Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
| Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
| Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BOLT News
- 2 days ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 3 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 8 months ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire